Treatment of osteoporosis and prevention of new fractures: Role of intravenously administered bisphosphonates

Endocrine Practice

Volumn 15, Issue 5, 2009, Pages 483-493

  Cosman, Felicia ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b HELEN HAYES HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; GERANYLTRANSFERASE; IBANDRONIC ACID; PLACEBO; PREDNISONE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE;

AGE DISTRIBUTION; BODY HEIGHT; BODY WEIGHT; BONE DENSITY; BONE MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; COST EFFECTIVENESS ANALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME INHIBITION; FRAGILITY FRACTURE; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; HUMERUS; HYPOCALCEMIA; JAW OSTEONECROSIS; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PAGET BONE DISEASE; PARATHYROID GLAND; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN PRENYLATION; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SCORING SYSTEM; SEX DIFFERENCE; SINGLE DRUG DOSE; SPINE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY; WRIST; FEMALE; FRACTURE; MALE;

DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 70449711520     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP08306.ORR1     Document Type: Review

References (76)

1. Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone. 2006;38(2 suppl 1):S4-S9.
2. National Osteoporosis Foundation. Fast Facts on Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008. http://www.nof.org/ osteoporosis/diseasefacts. htm. Accessed for verification April 27, 2009.
3. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22:465-475.
4. International Osteoporosis Foundation. Invest in Your Bones. Quality of Life: Why Prevent the First Fracture? Nyon, Switzerland: International Osteoporosis Foundation, 2003. http://www.iofbonehealth.org/ download/osteofound/filemanager/publications/pdf/quality-of-life.pdf. Accessed for verification April 27, 2009.
5. International Osteoporosis Foundation. Facts and Statistics About Osteoporosis and Its Impact. Nyon, Switzerland: International Osteoporosis Foundation, 2007. http://www.iofbonehealth.org/facts-and-statistics.html. Accessed for verification April 27, 2009.
6. Gabriel SE, Tosteson AN, Leibson CL, et al. Direct medical costs attributable to osteoporotic fractures. Osteoporos Int. 2002;13:323-330.
7. Hallberg I, Rosenqvist AM, Kartous L, Löfman O, Wahlström O, Toss G. Health-related quality of life after osteoporotic fractures. Osteoporos Int. 2004;15:834-841.
8. National Osteoporosis Foundation. Advocacy News and Updates. America's Bone Health: The State of Osteoporosis and Low Bone Mass. Washington, DC: National Osteoporosis Foundation, 2008. http://www.nof.org/advocacy/ prevalence/index.htm. Accessed for verification April 27, 2009.
9. Chapurlat RD, Delmas PD. Drug insight: bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab. 2006;2:211-219.
10. Fosamax [package insert]. Whitehouse Station, NJ: Merck & Co., Inc., 2007.
11. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165: 2414-2419.
12. Delmas PD, van de Langerijt L, Watts NB, et al (IMPACT Study Group). Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res. 2005;20:557-563.
13. Andrade SE, Majumdar SR, Chan KA, et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med. 2003;163: 2052-2057.
14. Siris ES, Miller PD, Barrett-Conner E, et al. Identification and fracture outcomes of undiagnosed low bone density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001;286: 2815-2822.
15. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164:1108-1112.
16. Pasco JA, Seeman E, Henry MJ, Merriman EN, Nicholson GC, Kotowicz MA. The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int. 2006;17:1404-1409.
17. Cranney A, Jama SA, Tsang JF, Josse RG, Leslie WD. Low bone mineral density and fracture burden in postmenopausal women. CMAJ. 2007;177:575-580.
18. Kanis JA, Burlet N, Cooper C, et al (European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis [ESCEO]). European guidance for the diagnosis and management of osteoporosis in postmenopausal women [published correction appears in Osteoporos Int. 2008;19:1103-1104]. Osteoporos Int. 2008;19:399-428.
19. Gehlbach SH, Avrunin JS, Puleo E, Spaeth R. Fracture risk and antiresorptive medication use in older women in the USA. Osteoporos Int. 2007;18:805-810.
20. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008. http://www.nof.org/professionals/NOF-Clinicians-Guide.pdf. Accessed for verification April 27, 2009.
21. Green JR. Bisphosphonates: preclinical review. Oncologist. 2004;9(suppl 4):3-13.
22. Dunford JF, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharm Exp Ther. 2001;296:235-242.
23. Black DM, Cummings SR, Karpf DB, et al (Fracture Intervention Trial Research Group). Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.
24. Harris ST, Watts NB, Genant HK, et al (Vertebral Efficacy With Risedronate Therapy [VERT] Study Group). Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282:1344-1352.
25. Reginster J, Minne HW, Sorensen OH, et al (Vertebral Efficacy With Risedronate Therapy [VERT] Study Group). Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000;11:83-91.
26. Chesnut CH III, Skag A, Christiansen C, et al (Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe [BONE]). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241-1249.
27. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study [published correction appears in Ann Rheum Dis. 2008;67:280]. Ann Rheum Dis. 2006;65:654-661.
28. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the Dosing IntraVenous Administration study. Arthritis Rheum. 2006; 54:1838-1846.
29. Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin. 2008;24:237-245.
30. Cranney A, Wells GA, Yetisir E, et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int. 2009;20:291-297.
31. Sebba AI, Emkey RD, Kohles JD, Sambrook PN. Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis. Bone. 2009;44:423-427.
32. Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int. 2007;18:711-719.
33. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81:1013-1022.
34. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15:1003-1008.
35. Briesacher BA, Andrade SE, Yood RA, Kahler KH. Consequences of poor compliance with bisphosphonates. Bone. 2007;41:882-887.
36. Weycker D, Macarios D, Edlesberg J, Oster G. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int. 2007;18:271-277.
37. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2008;19:811-818.
38. Earnshaw SR, Graham CN, Ettinger B, Amonkar MM, Lynch NO, Middelhoven H. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Curr Med Res Opin. 2007;23:2517-2529.
39. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007; 18:1023-1031.
40. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int. 2003;14:259-262.
41. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005;80:856-861.
42. Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther. 2006;28:236-242.
43. Cooper A, Drake J, Brankin E (PERSIST Investigators). Treatment persistence with once-monthly ibandronate and patient support vs once-weekly alendronate: results from the PERSIST study. Int J Clin Pract. 2006;60:896-905.
44. Weiss TW, Henderson SC, McHorney CA, Cramer JA. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr Res Med Opin. 2007;23:2193-2203.
45. Eisman JA, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol. 2008;35:488-497.
46. Black DM, Delmas PD, Eastell R, et al (HORIZON Pivotal Fracture Trial). Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-1822.
47. Lyles KW, Colón-Emeric CS, Magaziner JS, et al (HORIZON Recurrent Fracture Trial). Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799-1809.
48. Eriksen EF, Lyles KW, Colón-Emeric CS, et al. Antifracture efficacy and reduction of mortality in relation to timing of first dose of zoledronic acid after hip fracture [published online ahead of print March 3, 2009]. J Bone Miner Res. doi:10.1359/jbmr090209.
49. Reclast [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2009.
50. Reid DM, Devogelaer JP, Saag K, et al (HORIZON Investigators). Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373: 1253-1263.
51. Adami S, Felsenberg D, Christiansen C, et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone. 2004;34:881-889.
52. Khosla S, Burr D, Cauley J, et al (American Society for Bone and Mineral Research). Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479-1491.
53. Woo SB, Hellstein JW, Kalmar JR. Narrative (corrected) review: bisphosphonates and osteonecrosis of the jaws [published correction appears in Ann Intern Med. 2006;145:235]. Ann Intern Med. 2006;144:753-761.
54. Felsenberg D, Hoffmeister B, Amling M, Mundlos S, Seibel MJ, Fratzl P. Onkologie: Kiefernekrosen nach hoch dosierter bisphosphonattherapie [article in Dutch]. Deutsches Arztebattl. 2006;103:A-3078-A-3081.
55. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dental Assoc. 2006;137:1144-1150.
56. Grbic JT, Landesberg R, Lin SQ, et al (Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial Research Group). Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial. J Am Dent Assoc. 2008;139:32-40.
57. Zometa [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2007.
58. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082.
59. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation [letter]. N Engl J Med. 2007;356: 1895-1896.
60. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
61. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003;349:1216-1226.
62. Black DM, Greenspan SL, Ensrud KE, et al (PaTH Study Investigators). The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349:1207-1215.
63. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005;26:688-703.
64. Gasser JA, Ingold P, Venturiere A, Green JR. Chronic subcutaneous, but not single intravenous dosing of rats with bisphosphonates results in reduced bone anabolic response to PTH [abstract F386]. J Bone Miner Res. 2006;21(suppl 1):S113.
65. Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med. 2005;353:566-575.
66. Lindsay R, Cosman F, Bostrom M, Zhou H, Nieves J, Dempster DW. Histomorphometric and biochemical bone formation responses to first and second cycles of teriparatide treatment [abstract 1169]. J Bone Miner Res. 2008;23(suppl 1):S48.
67. Cosman F, Wermers RA, Recknor C, et al. Efficacy of adding teriparatide versus switching to teriparatide in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate [abstract O423]. J Bone Miner Res. 2007;22(suppl 1):S89.
68. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89:349-353.
69. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294-1301.
70. Armamento-Villareal R, Napoli N, Pinwar V, Novack D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med. 2006;355: 2048-2050.
71. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008;39:224-231.
72. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22:346-350.
73. Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008;93:2948-2952.
74. Black DM, Schwartz AV, Ensrud KE, et al (FLEX Research Group). Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX); a randomized trial. JAMA. 2006;296:2927-2938.
75. Schwartz AV, Bauer DC, Cauley JA, et al. Efficacy of continued alendronate for fractures in women without prevalent vertebral fracture: the FLEX trial [abstract 1057]. J Bone Miner Res. 2007;22(suppl 1):S16.
76. McClung M, Recker R, Miller P, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone. 2007;41:122-128.